Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market
1. EXAS projects $2.76B in 2024 sales, surpassing expectations. 2. Screening revenue expected at $2.104B, a 13% increase. 3. Third-quarter anticipated revenue of $713M, exceeding consensus forecasts. 4. Three new cancer tests to launch in 2025 enhance growth potential. 5. Goldman Sachs notes CRC screening could give EXAS a competitive edge.